Fosun Pharma (600196.SH) subsidiary obtains drug registration approval from the US FDA.

Zhixin Finance APP News, Fosun Pharma (600196.SH) announced that recently, its holding subsidiary Shanghai Henlius Biotech, Inc. and its holding subsidiary have received approval from the US FDA (Food and Drug Administration) for the Biologics License Application (BLA) of 60mg/mL and 120mg/1.7mL specifications of the self-developed geptanolimab injection (project code: HLX14).